Literature DB >> 2327400

Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.

J H Brock1, J Licéaga, H M Arthur, G J Kontoghiorghes.   

Abstract

The effect of several iron chelators on iron uptake and release by mouse peritoneal macrophages has been investigated. The 1,2-dimethyl (L1) and 1-ethyl-2-methyl (L1NEt) derivatives of 3-hydroxypyrid-4-one markedly enhanced iron mobilisation from macrophages pulsed with 59Fe-transferrin-antitransferrin immune complexes and were more effective than desferrioxamine, maltol, or mimosine. Release increased with increasing chelator concentration. None of the chelators donated significant amounts of iron to macrophages, and none showed any cytotoxic effect. The synthetic alpha-ketohydroxypyridine chelators may therefore be active in removing iron from the reticuloendothelial system as well as from hepatocytes, and indeed may be superior to desferrioxamine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2327400     DOI: 10.1002/ajh.2830340106

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  7 in total

1.  New developments and controversies in iron metabolism and iron chelation therapy.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2016-03-26

Review 2.  Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology.

Authors:  George J Kontoghiorghes
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

Review 3.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 4.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

5.  Questioning Established Theories and Treatment Methods Related to Iron and Other Metal Metabolic Changes, Affecting All Major Diseases and Billions of Patients.

Authors:  George J Kontoghiorghes
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

Review 6.  New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.

Authors:  George J Kontoghiorghes; Annita Kolnagou; Theodora Demetriou; Marina Neocleous; Christina N Kontoghiorghe
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

Review 7.  Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases.

Authors:  George J Kontoghiorghes; Christina N Kontoghiorghe
Journal:  Cells       Date:  2020-06-12       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.